Package insert for Janssen's Darunavir and Cobicistat tablets, detailing composition, dosage, indications, and safety information.
This document provides the official package insert for Darunavir and Cobicistat tablets (Prezcobix) marketed by Janssen. It includes the drug’s composition, physical description, approved indications for HIV‑1 infection, recommended dosage, and administration instructions.
Safety information covers contraindications, precautions, drug‑drug interactions, adverse reactions, pharmacokinetic properties, storage conditions, packaging details, and regulatory identifiers for the product. This manual is written in Chinese.
| Darunavir per tablet | 800 mg (equivalent to 867.28 mg darunavir ethanol complex) |
|---|---|
| Molecular formula (Darunavir) | C27H37N3O7S |
| Molecular weight (Darunavir) | 547.66 g/mol |
| Shelf life | 24 months |
The recommended dosage for adult patients is one tablet taken once daily with food.
The most frequently reported adverse reactions are diarrhea, nausea, and rash.